Chemistry:MDMB-5Br-INACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C15H18BrN3O3 |
| Molar mass | 368.231 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-5Br-INACA is an indazole-3-carboxamide derivative which has been sold as a designer drug.[1] Surprisingly it appears to produce psychoactive activity despite the lack of a "tail" group at the indazole 1-position, but is of relatively low potency and has been encountered being misrepresented as other illicit drugs such as MDMA.[2][3]
Use as a precursor
MDMB-5Br-INACA is believed to be used as a precursor in the synthesis of synthetic cannabinoids. It has been sold online as "half finished" synthetic cannabinoids, sometimes as a "chemistry kit" with other compounds required to complete the reaction. This reaction would complete MDMB-5Br-INACA by giving it a "tail" group required for high cannabinoid activity. Other precursors lacking a tail chain have also been marketed such as (ADB-5-Br-INACA), (CH-IATA), (ADB-IACA), and (ADB-5’Br-EZO-CA). This may be due to increasing legality changes worldwide on synthetic cannabinoids.[4][5]
Legality
In the United States, MDMB-5Br-INACA is unscheduled at the federal level as of May 22nd, 2023.
North Dakota has placed MDMB-5Br-INACA (along with ADB-5'Br-BINACA, ADB-5'Br-BUTINACA and ADB-5-Br-INACA) into Schedule I on 04/27/2023.[6]
See also
References
- ↑ "CFSRE Analysis Report". Indianapolis-Marion County Forensic Services Agency. 17 May 2022. https://www.npsdiscovery.org/wp-content/uploads/2022/05/MDMB-5Br-INACA_051722_CFSRE-Chemistry_Report.pdf.
- ↑ "Drug testers warn of new synthetic cannabinoid being sold as MDMA". New Zealand Herald. 5 August 2022. https://www.nzherald.co.nz/nz/drug-testers-warn-of-new-synthetic-cannabinoid-being-sold-as-mdma/T35763CVQZHPV6LBZEQQ6FPX3U/.
- ↑ "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. October 2023. doi:10.1002/dta.3592. PMID 37903509.
- ↑ Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
- ↑ Andrews R, et al. From JWH-018 to OXIZIDS: Structural evolution of synthetic cannabinoids in the European Union from 2008 to present day. Drug Testing and Analysis 2023; 15(4):378-387. doi:10.1002/dta.3422
- ↑ "AN ACT to amend and reenact sections 19-03.1-05, 19-03.1-11, and 19-03.1-13 of the North Dakota Century Code, relating to the scheduling of controlled substances; and to declare an emergency.". Sixty-eighth Legislative Assembly of North Dakota in Regular Session. 3 January 2023. https://www.ndlegis.gov/prod/assembly/68-2023/regular/documents/23-8099-04000.pdf.
 |  |
